Envoy Medical Secures Three New Patents, Strengthening Leadership in Fully Implantable Hearing Technology

Patents issued in the U.S., Australia, and Hong Kong advance Envoy Medical's innovation pipeline and protect next-generation cochlear implant solutions for individuals living with hearing loss.

White Bear Lake, Minnesota--(Newsfile Corp. - August 20, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of three new patents across the United States, Australia, and Hong Kong. These patents expand the company's global intellectual property portfolio and mark another strategic step in delivering next-generation cochlear implant solutions that offer patients discreet, 24/7 hearing experience without the limitation of externally worn components.

The U.S. Patent & Trademark Office has issued the following patent to Envoy Medical:

• U.S. Patent No. 12,390,634, on August 19, 2025. The title of the patent is Fully Implantable Modular Cochlear Implant System. This patent relates to cochlear implant systems having a signal processor and an implantable battery and/or communication module having a signal generator that generates digital signals for communicating to the signal processor. The signal processor and the implantable battery and/or communication module include circuitry, a can that houses and surrounds the circuitry, and an impedance between the circuitry and the can to reduce unintended electrical communication between the circuitry and a cochlear electrode of the cochlear implant system.

The Australian Patent Office has issued the following patent to Envoy Medical:

• Australian Patent No. 2022254630, on July 17, 2025. The title is Cochlear Implant System with Electrode Impedance Diagnostics. This patent relates to electrode impedance diagnostics in cochlear implant systems. A cochlear implant system determines an impedance associated with a current path from a source element to a return electrode and determines one or more stimulation parameters for the source element based on the impedance. An example stimulation parameter is a compliance voltage for the source element to provide a prescribed current.

The Hong Kong Patent Office has issued the following patent to Envoy Medical:

• Hong Kong Patent No. 40101898, on May 16, 2025. The title is Cochlear Implant Stimulation Calibration. This patent relates to calibrating current flow in a cochlear implant system. A switching network is controlled to place a source element of a cochlear implant system in communication with a testing circuit. An amount of electrical current provided to the testing circuit is determined and the output of the source element is adjusted based on the determined amount of electrical current.

"Our patent portfolio has many critical building blocks to redefine what's possible for hearing restoration solutions. These additional patents strengthen our position. By expanding our global patent portfolio, Envoy Medical is not only protecting groundbreaking innovations, but also supporting our mission to deliver life-changing, fully implantable solutions to more people around the world. This momentum brings us one step closer to eliminating daily limitations faced by millions of people living with hearing loss," commented Brent Lucas, CEO of Envoy Medical.

For more information about Envoy Medical's innovation pipeline and intellectual property portfolio, visit www.envoymedical.com.

To be added to the Envoy Medical email distribution list, please email Envoy@kcsa.com with COCH in the subject line.

About Envoy Medical, Inc.

Envoy Medical (NASDAQ: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.

About the Fully Implanted Acclaim® Cochlear Implant

We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.

The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.

The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.

CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.

About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)

The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.

*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.

Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.

Forward-Looking Statements https://landing.envoymedical.com/important-information